Uterine leiomyomas is the commonest benign tumour of the female genital tract. It lead to
menorrhagia, anaemia, pain and pressure symptoms. Due to the enlarged uterus, the use of
minimal invasive surgery is limited. There is also increase risk of intraoperative blood
transfusion. Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM).
Preoperative use of Ulipristal for 12 weeks has been shown to decrease uterine bleeding,
fibroid volume, pre-operative anaemia and symptoms severity. However there is still lacking
evidence in terms of long term safety and efficacy, especially in Chinese population. The aim
of the present study is to evaluate the effect and safety on preoperative use of Ulipristal
on fibroid.